keyword
MENU ▼
Read by QxMD icon Read
search

prolactin antipsychotic

keyword
https://www.readbyqxmd.com/read/28478771/evaluation-of-the-long-term-safety-and-tolerability-of-cariprazine-in-patients-with-schizophrenia-results-from-a-1-year-open-label-study
#1
Andrew J Cutler, Suresh Durgam, Yao Wang, Raffaele Migliore, Kaifeng Lu, István Laszlovszky, György Németh
OBJECTIVE: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. The efficacy and safety of cariprazine was established in three randomized, double-blind, placebo-controlled, 6-week trials in patients with acute exacerbation of schizophrenia. This 53-week study evaluated the long-term safety and tolerability of cariprazine in patients with schizophrenia...
May 8, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28461752/the-effectiveness-and-safety-of-amisulpride-in-chinese-patients-with-schizophrenia-who-switch-from-risperidone-or-olanzapine-a-subgroup-analysis-of-the-escape-study
#2
Ying Liang, Xin Yu
INTRODUCTION: Second-generation antipsychotics show significant interpatient variability in treatment response and side-effect profiles, and the majority of patients with schizophrenia require multiple treatment changes. This subgroup analysis of the ESCAPE study evaluated the efficacy and safety of amisulpride in Chinese patients with schizophrenia who switched from risperidone or olanzapine. METHODS: ESCAPE was a prospective, open-label, multicenter, single-arm Phase IV study in which Chinese patients with an ICD-10 diagnosis of schizophrenia received amisulpride for 8 weeks...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28437810/hyperprolactinemia-and-the-association-with-all-cause-mortality-and-cardiovascular-mortality
#3
Jesper Krogh, Christian Selmer, Christian Torp-Pedersen, Gunnar Hilmar Gislason, Caroline Kistorp
Hyperprolactinemia has been suspected to increase mortality risk, but the available data are conflicting. The objective of this study was to estimate the association between hyperprolactinemia and all-cause and cardiovascular mortality among patients referred for assessment of prolactin. For this study, adults with no prio pituitary disease who underwent prolactin assessment at 3 university Hospitals in Denmark between 2001 and 2011 were included in a retrospective cohort study. A total of 3 633 patients with a median follow-up time of 5...
April 24, 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/28372526/adjunctive-metformin-for-antipsychotic-related-hyperprolactinemia-a-meta-analysis-of-randomized-controlled-trials
#4
Wei Zheng, Xin-Hu Yang, Dong-Bin Cai, Gabor S Ungvari, Chee H Ng, Nan Wang, Yu-Ping Ning, Yu-Tao Xiang
Hyperprolactinemia is a common and severe antipsychotic-induced adverse drug reaction. This meta-analysis of randomized controlled trials systematically examined the efficacy and safety of adjunctive metformin for antipsychotic-related hyperprolactinemia in schizophrenia patients. Two independent investigators searched, extracted, and synthesized data. Weighted mean differences and risk ratios with their 95% confidence intervals were calculated using random effect model. Four randomized controlled trials ( n=509) comparing adjunctive metformin ( n=253) with the control groups ( n=256), lasting 22...
May 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28338545/risperidone-and-cardiometabolic-risk-in-children-and-adolescents-clinical-and-instrumental-issues
#5
Emilia Matera, Lucia Margari, Vincenzo Ostilio Palmieri, Giuseppina Zagaria, Roberto Palumbi, Francesco Margari
PURPOSE/BACKGROUND: Although second-generation antipsychotics are used to treat and manage symptoms for several psychiatric disorders, data about their adverse effects in developmental age are limited. The aim of this prospective observational study was to verify the cardiovascular and metabolic risk in a sample of antipsychotic-naive children/adolescent patients starting risperidone therapy. METHODS: Twenty-two patients, younger than 18 years, were recruited. The assessment included anthropometric data, cardiovascular parameters, blood tests, and ultrasonographic abdominal study...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28321467/-sexual-dysfunction-associated-with-psychotropic-drugs-and-treatment-options
#6
M Berner
BACKGROUND: Sexual dysfunction associated with psychotropic drugs is a threat to patient quality of life and a major reason for non-compliance. Psychotropic agents can impair the sexual response in different ways due to their neurobiological mode of action. OBJECTIVE: Presentation of the frequencies of sexual functional disorders for selected psychopharmacological groups and the available treatment modalities. METHODS: Literature search, selection and review of relevant studies...
March 20, 2017: Der Nervenarzt
https://www.readbyqxmd.com/read/28320371/possible-factors-influencing-the-duration-of-hospital-stay-in-patients-with-psychiatric-disorders-attempting-suicide-by-jumping
#7
Tsubasa Omi, Hiroshi Ito, Keisen Riku, Koji Kanai, Hiromune Takada, Satoshi Fujimi, Hidenori Matsunaga, Kazutaka Ohi
BACKGROUND: Patients with psychiatric disorders have a high rate of suicide. The present study investigated factors influencing hospital stays for Japanese patients with psychiatric disorders attempting suicide by jumping. METHODS: We diagnosed all suicide attempts (n = 113) by jumping based on the International Classification of Diseases 10th Revision (ICD-10) and investigated the mean hospital stays of patients with each diagnosis based on the ICD-10 code. We then analyzed differences in the demographic and clinical characteristics between the diagnostic groups to identify factors influencing the duration of hospital stay...
March 20, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28262171/partial-regimen-replacement-with-aripiprazole-reduces-serum-prolactin-in-patients-with-a-long-history-of-schizophrenia-a-case-series
#8
Keiko Naono-Nagatomo, Hisao Naono, Hiroshi Abe, Ryuichiro Takeda, Hideki Funahashi, Daisuke Uchimura, Yasushi Ishida
AIM: Aripiprazole (ARP) is a popular antipsychotic drug that has demonstrated ameliorative effects on hyperprolactinemia. However, no study to date has studied the utility of ARP in patients with a long history of schizophrenia and antipsychotic treatment. We therefore examined the effect of partial antipsychotic regimen replacement with ARP on hyperprolactinemia induced by chronic antipsychotic use in patients with schizophrenia. METHODS: Sixteen patients with a schizophrenia diagnosis (F2) based on the International Classification of Diseases (version 10) were recruited...
February 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28252452/reduced-sexual-dysfunction-with-aripiprazole-once-monthly-versus-paliperidone-palmitate-results-from-qualify
#9
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Karina Hansen, Dieter Naber
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM 400), a dopamine D2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (PP), a dopamine D2 receptor antagonist, on the Heinrichs-Carpenter Quality-of-Life Scale (QLS) in patients with schizophrenia aged 18-60 years. Sexual dysfunction (Arizona Sexual Experience Scale) and serum prolactin levels were also assessed...
May 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28223031/effects-of-aripiprazole-quetiapine-and-ziprasidone-on-plasma-prolactin-levels-in-individuals-with-first-episode-nonaffective-psychosis-analysis-of-a-randomized-open-label-1year-study
#10
Benedicto Crespo-Facorro, Victor Ortiz-Garcia de la Foz, Paula Suarez-Pinilla, Elsa M Valdizan, Rocío Pérez-Iglesias, Jose Antonio Amado-Señaris, M Teresa Garcia-Unzueta, Javier Labad, Christopher Correll, Rosa Ayesa-Arriola
RATIONALE: Hyperprolactinemia is considered a troubling adverse effect of antipsychotics. Direct comparisons among second generation antipsychotics are scant in clinical practice. We hypothesize prolactin-sparing second-generation antipsychotics may have differential effects on prolactin levels and that they may be influenced by sex. OBJECTIVES: To explore the differential effect of three widely used prolactin-sparing antipsychotics, aripiprazole, quetiapine and ziprasidone, on prolactin plasma levels in first episode non-affective psychosis during a 1year of treatment...
February 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28219485/acute-antipsychotic-treatment-of-children-and-adolescents-with-schizophrenia-spectrum-disorders-a-systematic-review-and-network-meta-analysis
#11
REVIEW
Anne Katrine Pagsberg, Simon Tarp, Dorte Glintborg, Anne Dorte Stenstrøm, Anders Fink-Jensen, Christoph Ulrich Correll, Robin Christensen
OBJECTIVE: To determine the comparative efficacy and safety of antipsychotics for youth with early-onset schizophrenia using network meta-analytic methods combining direct and indirect trial data. METHOD: The authors systematically searched MEDLINE, the Cochrane Library, and clinicaltrials.gov and selected randomized controlled trials allocating youth with schizophrenia spectrum disorders to a (non-clozapine) antipsychotic versus placebo or another antipsychotic...
March 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28214176/sex-differences-in-prolactin-levels-in-emerging-psychosis-indication-for-enhanced-stress-reactivity-in-women
#12
Sarah Ittig, Erich Studerus, Ulrike Heitz, Stephanie Menghini-Müller, Katharina Beck, Laura Egloff, Letizia Leanza, Christina Andreou, Anita Riecher-Rössler
BACKGROUND: Hyperprolactinemia is a known side effect of antipsychotics. In recent reports it has also been shown in antipsychotic-naïve at-risk mental state (ARMS) and first-episode psychosis (FEP) patients. Prolactin is not only involved in reproduction and lactation, but is also synthesized in response to stress. As stress is thought to play an important role in the onset and relapse of schizophrenia, the aim of this study was to further elucidate the influence of prolactin in emerging psychosis...
February 14, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28199787/prolactin-elevating-antipsychotics-and-the-risk-of-endometrial-cancer
#13
Adi J Klil-Drori, Hui Yin, Haim A Abenhaim, Guillaume Galbaud du Fort, Laurent Azoulay
BACKGROUND: The use of antipsychotics may increase the risk of endometrial cancer through elevation of prolactin levels. We investigated the association between antipsychotics that are known to cause prolactin elevation and the risk of endometrial cancer. METHODS: In data from the United Kingdom Clinical Practice Research Datalink, all women who were newly treated with antipsychotics from 1990-2013 were identified and followed until 2014. Within this cohort of antipsychotic users, a nested case-control analysis was conducted...
February 14, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28129701/how-gender-affects-the-pharmacotherapeutic-approach-to-treating-psychosis-a-systematic-review
#14
REVIEW
Bettina Lange, Juliane K Mueller, F Markus Leweke, J Malte Bumb
The effectiveness, effective dosages and side effect profiles of antipsychotic medication differ significantly between the sexes. Areas covered: We present a systematic review of gender-differences in the treatment of psychosis focusing on randomized, controlled trials and meta-analyses. Expert opinion: Despite many years of research, the database on gender-differences affecting the pharmacotherapeutic approach to treating psychosis is insufficient. Currently, the US National Institute of Health encouraged the enrolment of female participants in federally supported phase III clinical trials to increase the data available of female patients...
March 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28127934/antipsychotic-augmentation-vs-monotherapy-in-schizophrenia-systematic-review-meta-analysis-and-meta-regression-analysis
#15
Britta Galling, Alexandra Roldán, Katsuhiko Hagi, Liz Rietschel, Frozan Walyzada, Wei Zheng, Xiao-Lan Cao, Yu-Tao Xiang, Mathias Zink, John M Kane, Jimmi Nielsen, Stefan Leucht, Christoph U Correll
Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and costly with unclear evidence for its efficacy and safety. We conducted a systematic literature search and a random effects meta-analysis of randomized trials comparing augmentation with a second antipsychotic vs. continued antipsychotic monotherapy in schizophrenia. Co-primary outcomes were total symptom reduction and study-defined response. Antipsychotic augmentation was superior to monotherapy regarding total symptom reduction (16 studies, N=694, standardized mean difference, SMD=-0...
February 2017: World Psychiatry: Official Journal of the World Psychiatric Association (WPA)
https://www.readbyqxmd.com/read/28108225/female-schizophrenia-patients-and-risk-of-breast-cancer-a-population-based-cohort-study
#16
Ana Isabel Wu Chou, Yu-Chiao Wang, Cheng-Li Lin, Chia-Hung Kao
OBJECTIVE: Breast cancer is the most common type of cancer in women. This population-based cohort study aimed to examine the association between breast cancer in female schizophrenia patients and its association with the use of antipsychotics drugs. METHODS: All study subjects were selected from the Taiwan Insurance Claims Data (1998-2008). We compared the risk for breast cancer between female schizophrenia patients receiving antipsychotics (n=29,641) with female patients without any serious mental illnesses nor receiving antipsychotic drugs (n=59,282)...
January 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28008301/iloperidone-in-the-treatment-of-schizophrenia-an-evidence-based-review-of-its-place-in-therapy
#17
REVIEW
Fernanda S Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
INTRODUCTION: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies. AIM: To review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia...
2016: Core Evidence
https://www.readbyqxmd.com/read/27932884/a-randomized-trial-of-aripiprazole-vs-blonanserin-for-the-treatment-of-acute-schizophrenia-and-related-disorders
#18
Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Tomohiko Mukai, Masatsugu Moriwaki, Hideaki Tabuse, Kiyoshi Fujita, Nakao Iwata
OBJECTIVE: There has been no direct comparison of aripiprazole and blonanserin for schizophrenia treatment. We conducted a 24-week, rater-masked, randomized trial of aripiprazole (6-30 mg/d) vs blonanserin (4-24 mg/d) in schizophrenia patients who were not taking any antipsychotic medication for more than 2 weeks before enrollment (UMIN000011194). METHODS: The primary outcome measure for efficacy was improvement of Positive and Negative Syndrome Scale (PANSS) total score at week 24...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27866695/does-formulation-matter-a-systematic-review-and-meta-analysis-of-oral-versus-long-acting-antipsychotic-studies
#19
REVIEW
Giovanni Ostuzzi, Irene Bighelli, Ryuhei So, Toshi A Furukawa, Corrado Barbui
Recently, many authors highlighted the potential advantages of a broader prescription of long-acting injectable antipsychotics (LAIs) based on various assumptions, including favorable pharmacokinetic features. In this systematic review, data from randomized controlled trials comparing LAIs versus the oral formulation of the same antipsychotic were meta-analyzed in order to ascertain whether the route of administration may be associated with a different efficacy and tolerability profile. Of 21 included studies, 18 contributed to the meta-analysis, providing data for risperidone, olanzapine, aripiprazole, zuclopenthixol, fluphenazine and haloperidol...
November 17, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27825323/prolactin-related-adverse-events-and-change-in-prolactin-levels-in-pediatric-patients-given-antipsychotics-for-schizophrenia-and-schizophrenia-spectrum-disorders-a-systematic-review
#20
Eric Druyts, Michael J Zoratti, Kabirraaj Toor, Ping Wu, Salmaan Kanji, Kiran Rabheru, Edward J Mills, Kristian Thorlund
BACKGROUND: Second-generation antipsychotics are commonly prescribed for pediatric patients with schizophrenia and schizophrenia spectrum disorders despite their lack of approval for use in children. Although considered a safer alternative to first-generation antipsychotics, there is evidence to suggest that second-generation antipsychotics may be associated with some adverse events as well as an increase in prolactin levels. The purpose of this review is to examine the risk of prolactin-related adverse events in pediatric patients using antipsychotics and to quantify changes in prolactin for this population...
November 9, 2016: BMC Pediatrics
keyword
keyword
51269
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"